Work

Abstract LB-141: Potent single agent activity of Ibrutinib (PCI-32765) in patients with chronic lymphocytic leukemia (CLL): clinical and translational results from an ongoing phase II study.

Year: 2013

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2013-lb-141

Authors: Adrian Wiestner, Sarah Herman, Rashida Mustafa, Janet Valdez, Jade Jones, Nakhle Saba, Andrew Lipsky, Diane C. Arthur, Gerald Marti, Francine Thomas, Irina Maric, Stefania Pittaluga, Xin Tian, Susan Soto, Georg Aue, Mohammed Z. Farooqui

Institutions: National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, Center for Cancer Research

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2057140561

Cites:

Cited by: 3

Related to: 10